Access the full text.
Sign up today, get DeepDyve free for 14 days.
David Killock (2012)
Experimental arthritis: NGF promotes synovial nerve sproutingNature Reviews Rheumatology, 8
W. Marks, R. Bartus, J. Siffert, C. Davis, A. Lozano, N. Boulis, J. Vitek, M. Stacy, Dennis Turner, L. Verhagen, R. Bakay, R. Watts, B. Guthrie, J. Jankovic, R. Simpson, M. Tagliati, R. Alterman, M. Stern, G. Baltuch, P. Starr, P. Larson, J. Ostrem, J. Nutt, K. Kieburtz, J. Kordower, C. Olanow (2010)
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trialThe Lancet Neurology, 9
M. Tuszynski, L. Thal, M. Pay, D. Salmon, Hoi U, R. Bakay, P. Patel, A. Blesch, H. Vahlsing, G. Ho, G. Tong, S. Potkin, J. Fallon, L. Hansen, E. Mufson, J. Kordower, C. Gall, J. Conner (2005)
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer diseaseNature Medicine, 11
David Holtzman, Yiwen Li, Chen Ks, Fred Gage, Charles Epstein, W. Mobley (1993)
Nerve growth factor reverses neuronal atrophy in a Down syndrome model of age‐related neurodegenerationNeurology, 43
R. Levi‐montalcini, V. Hamburger (1951)
Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo.The Journal of experimental zoology, 116 2
M. Rafii, T. Baumann, R. Bakay, J. Ostrove, J. Siffert, A. Fleisher, C. Herzog, David Barba, M. Pay, David Salmon, Y. Chu, J. Kordower, K. Bishop, D. Keator, S. Potkin, R. Bartus (2014)
A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's diseaseAlzheimer's & Dementia, 10
M. Goedert, A. Fine, D. Dawbarn, G. Wilcock, M. Chao (1989)
Nerve growth factor receptor mRNA distribution in human brain: normal levels in basal forebrain in Alzheimer's disease.Brain research. Molecular brain research, 5 1
J. Conner, D. Muir, S. Varon, T. Hagg, M. Manthorpe (1992)
The localization of nerve growth factor‐like immunoreactivity in the adult rat basal forebrain and hippocampal formationJournal of Comparative Neurology, 319
Ronald Mandel, Fred Gage, D. Clevenger, S. Spratt, Richard Snyder, Stuart Leff (1999)
Nerve Growth Factor Expressed in the Medial Septum Followingin VivoGene Delivery Using a Recombinant Adeno-Associated Viral Vector Protects Cholinergic Neurons from Fimbria-Fornix Lesion-Induced DegenerationExperimental Neurology, 155
A. Wong, J. Yeung, Sophie Payne, J. Keast, P. Osborne (2015)
Neurite outgrowth in normal and injured primary sensory neurons reveals different regulation by nerve growth factor (NGF) and arteminMolecular and Cellular Neuroscience, 65
D. Kaplan, F. Miller (2000)
Neurotrophin signal transduction in the nervous systemCurrent Opinion in Neurobiology, 10
A. Nagahara, M. Mateling, I. Kovács, Ling Wang, S. Eggert, E. Rockenstein, E. Koo, E. Masliah, M. Tuszynski (2013)
Early BDNF Treatment Ameliorates Cell Loss in the Entorhinal Cortex of APP Transgenic MiceThe Journal of Neuroscience, 33
Ks Chen, F. Gage (1995)
Somatic gene transfer of NGF to the aged brain: behavioral and morphological amelioration, 15
M. Tuszynski, J. Roberts, M. Senut, H. U, F. Gage (1996)
Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration.Gene therapy, 3 4
S. Counts, M. Nadeem, J. Wuu, S. Ginsberg, H. Saragovi, E. Mufson (2004)
Reduction of cortical TrkA but not p75NTR protein in early‐stage Alzheimer's diseaseAnnals of Neurology, 56
K. Bankiewicz, J. Forsayeth, J. Eberling, R. Sánchez-Pernaute, P. Pivirotto, J. Bringas, P. Herscovitch, R. Carson, W. Eckelman, B. Reutter, J. Cunningham (2006)
Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC.Molecular therapy : the journal of the American Society of Gene Therapy, 14 4
A. Nagahara, D. Merrill, G. Coppola, Shingo Tsukada, B. Schroeder, G. Shaked, Ling Wang, A. Blesch, A. Kim, J. Conner, E. Rockenstein, M. Chao, E. Koo, D. Geschwind, E. Masliah, A. Chiba, M. Tuszynski (2009)
Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's diseaseNature Medicine, 15
S. Scott, E. Mufson, Janaína Weingartner, K. Skau, K. Crutcher (1995)
Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis, 15
G. Wenk (1997)
The Nucleus Basalis Magnocellularis Cholinergic System: One Hundred Years of ProgressNeurobiology of Learning and Memory, 67
J. Conner, M. Darracq, Jeffrey Roberts, M. Tuszynski (2001)
Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation.Proceedings of the National Academy of Sciences of the United States of America, 98 4
M. Tuszynski, Fred Gage (1995)
Bridging grafts and transient nerve growth factor infusions promote long-term central nervous system neuronal rescue and partial functional recovery.Proceedings of the National Academy of Sciences of the United States of America, 92 10
Laura Smithson, K. Krol, M. Kawaja (2014)
Neuronal degeneration associated with sympathosensory plexuses in the trigeminal ganglia of aged mice that overexpress nerve growth factorNeurobiology of Aging, 35
A. Martínez-Serrano, W. Fischer, A. Björklund (1995)
Reversal of age-dependent cognitive impairments and cholinergic neuron atrophy by NGF-secreting neural progenitors grafted to the basal forebrainNeuron, 15
Chih-Lung Lin, P. Heron, S. Hamann, George Smith, George Smith (2014)
Functional distinction between NGF-mediated plasticity and regeneration of nociceptive axons within the spinal cordNeuroscience, 272
J. Kordower, Shelley Winn, Yue-Ting Liu, E. Mufson, John Sladek, J. Hammang, E. Baetge, D. Emerich (1994)
The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor.Proceedings of the National Academy of Sciences of the United States of America, 91 23
Ingrid Johnsrude (2000)
Atlas of the Human BrainJournal of Psychophysiology, 14
A. Markowska, V. Koliatsos, S. Breckler, D. Price, D. Olton (1994)
Human nerve growth factor improves spatial memory in aged but not in young rats, 14
E. Mufson, Shuang Ma, John Dills, E. Cochran, S. Leurgans, J. Wuu, D. Bennett, S. Jaffar, M. Gilmor, A. Levey, J. Kordower (2002)
Loss of basal forebrain P75NTR immunoreactivity in subjects with mild cognitive impairment and Alzheimer's diseaseJournal of Comparative Neurology, 443
J. Winkler, G. Ramirez, H. Kuhn, D. Peterson, P. Day-Lollini, G. Stewart, M. Tuszynski, F. Gage, L. Thal (1997)
Reversible schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factorAnnals of Neurology, 41
M. Tuszynski, HS U, D. Amaral, F. Gage (1990)
Nerve growth factor infusion in the primate brain reduces lesion- induced cholinergic neuronal degeneration, 10
W. Fischer, K. Wictorin, Anders Björklund, Lawrence Williams, Silvio Varon, Fred Gage (1987)
Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factorNature, 329
M. Blurton-Jones, M. Kitazawa, H. Martínez-Coria, Nicholas Castello, F. Müller, J. Loring, T. Yamasaki, W. Poon, K. Green, F. LaFerla (2009)
Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer diseaseProceedings of the National Academy of Sciences, 106
P. Hadaczek, J. Eberling, P. Pivirotto, J. Bringas, J. Forsayeth, K. Bankiewicz (2010)
Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.Molecular therapy : the journal of the American Society of Gene Therapy, 18 8
J. Conner, S. Varon (1996)
Characterization of antibodies to nerve growth factor: assay-dependent variability in the cross-reactivity with other neurotrophinsJournal of Neuroscience Methods, 65
J. Kordower, C. Herzog, Biplob Dass, R. Bakay, James Stansell, M. Gasmi, R. Bartus (2006)
Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeysAnnals of Neurology, 60
L. Williams (1991)
Hypophagia is induced by intracerebroventricular administration of nerve growth factorExperimental Neurology, 113
ImportanceAlzheimer disease (AD) is the most common neurodegenerative disorder and lacks effective disease-modifying therapies. In 2001, we initiated a clinical trial of nerve growth factor (NGF) gene therapy in AD, the first effort at gene delivery in an adult neurodegenerative disorder. This program aimed to determine whether a nervous system growth factor prevents or reduces cholinergic neuronal degeneration in patients with AD. We present postmortem findings in 10 patients with survival times ranging from 1 to 10 years after treatment. ObjectiveTo determine whether degenerating neurons in AD retain an ability to respond to a nervous system growth factor delivered after disease onset. Design, Setting, and ParticipantsPatients in this anatomicopathological study were enrolled in clinical trials from March 2001 to October 2012 at the University of California, San Diego, Medical Center in La Jolla. Ten patients with early AD underwent NGF gene therapy using ex vivo or in vivo gene transfer. The brains of all 8 patients in the first phase 1 ex vivo trial and of 2 patients in a subsequent phase 1 in vivo trial were examined. Main Outcomes and MeasuresBrains were immunolabeled to evaluate in vivo gene expression, cholinergic neuronal responses to NGF, and activation of NGF-related cell signaling. In 2 patients, NGF protein levels were measured by enzyme-linked immunosorbent assay. ResultsAmong 10 patients, degenerating neurons in the AD brain responded to NGF. All patients exhibited a trophic response to NGF in the form of axonal sprouting toward the NGF source. Comparing treated and nontreated sides of the brain in 3 patients who underwent unilateral gene transfer, cholinergic neuronal hypertrophy occurred on the NGF-treated side (P < .05). Activation of cellular signaling and functional markers was present in 2 patients who underwent adeno-associated viral vectors (serotype 2)–mediated NGF gene transfer. Neurons exhibiting tau pathology and neurons free of tau expressed NGF, indicating that degenerating cells can be infected with therapeutic genes, with resultant activation of cell signaling. No adverse pathological effects related to NGF were observed. Conclusions and RelevanceThese findings indicate that neurons of the degenerating brain retain the ability to respond to growth factors with axonal sprouting, cell hypertrophy, and activation of functional markers. Sprouting induced by NGF persists for 10 years after gene transfer. Growth factor therapy appears safe over extended periods and merits continued testing as a means of treating neurodegenerative disorders.
JAMA Neurology – American Medical Association
Published: Oct 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.